Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus hyperthermia dose-finding study in recurrent head and neck or bladder cancer
NL-OMON28959Phase 1Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in head and neck squamous cell carcinoma (HNSCC) and bladder cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Dose-limiting toxicity and maximum tolerated dose. Started Jul 2016; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON28959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28959.